| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Receptors1
Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
A number of studies in experimental animal models point to an important role of Fc
Rs in autoimmunity and allergy. In this study, we investigate how the production of IgG, an early step in the chain of events leading to inflammation, is regulated by activating and inhibitory FcRs. IgG Abs are known to feedback-enhance Ab responses to soluble Ags, and this effect requires activating FcRs. To test proliferation of Th cells, mice were adoptively transferred with CD4+ T cells expressing a transgenic OVA-specific TCR before immunization with IgG2a anti-2,4,6-trinitrophenyl (TNP) plus OVA-TNP or with OVA-TNP alone. IgG2a induced a significant increase in OVA-specific T cell numbers, which preceded the OVA-specific Ab response and was dependent on the FcR chain. The role of the inhibitory FcRIIB in Ab responses was studied in mice lacking this receptor. Although IgG2a enhanced primary Ab responses, development of germinal centers, and immunological memory in wild-type mice, enhancement was markedly stronger in FcRIIB–/– mice. The presented data are compatible with the hypothesis that the mechanism behind IgG2a-mediated up-regulation of Ab responses involves increased Ag presentation to CD4+ T cells by FcR+ APCs. Our observations also illustrate the intricate immunoregulatory role of IgG Abs. On the one hand, they enhance Ab responses via activating FcRs, and on the other hand, they set an upper limit for the same Ab response via FcRIIB.
This article has been cited by other articles:
|
|
 |
|
  Y. M. Saenger, Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma Cancer Res., December 1, 2008; 68(23): 9884 - 9891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hjelm, M. C. I. Karlsson, and B. Heyman A Novel B Cell-Mediated Transport of IgE-Immune Complexes to the Follicle of the Spleen J. Immunol., May 15, 2008; 180(10): 6604 - 6610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Rawool, C. Bitsaktsis, Y. Li, D. R. Gosselin, Y. Lin, N. V. Kurkure, D. W. Metzger, and E. J. Gosselin Utilization of Fc Receptors as a Mucosal Vaccine Strategy against an Intracellular Bacterium, Francisella tularensis J. Immunol., April 15, 2008; 180(8): 5548 - 5557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al. Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Desai, S. O. Harbers, M. Flores, L. Colonna, M. P. Downie, A. Bergtold, S. Jung, and R. Clynes Fc{gamma} Receptor IIB on Dendritic Cells Enforces Peripheral Tolerance by Inhibiting Effector T Cell Responses J. Immunol., May 15, 2007; 178(10): 6217 - 6226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Schuurhuis, N. van Montfoort, A. Ioan-Facsinay, R. Jiawan, M. Camps, J. Nouta, C. J. M. Melief, J. S. Verbeek, and F. Ossendorp Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol., April 15, 2006; 176(8): 4573 - 4580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Brady Antibody-Mediated Immunomodulation: a Strategy To Improve Host Responses against Microbial Antigens Infect. Immun., February 1, 2005; 73(2): 671 - 678. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
